SCHEDULE 13G/A: Nantahala Capital Discloses 4.09% Stake in Trisalus Life Sciences

Nantahala Capital Management, along with Wilmot B. Harkey and Daniel Mack, reported a 4.09% beneficial ownership in Trisalus Life Sciences, Inc. as of September 30, 2025.

Summary

• Nantahala Capital Management, LLC, Wilmot B. Harkey, and Daniel Mack (the "Reporting Persons") collectively reported beneficial ownership of 2,040,245 shares of Trisalus Life Sciences, Inc. common stock.
• This ownership represents 4.09% of the total outstanding common stock of Trisalus Life Sciences, Inc.
• The Reporting Persons hold shared voting power and shared dispositive power over all 2,040,245 shares.
• Nantahala Capital Management, LLC is classified as an investment adviser, while Wilmot B. Harkey and Daniel Mack are identified as control persons in respect of the shares beneficially owned by Nantahala.
• The shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 5

Explanation: Neutral, as this is a routine disclosure of beneficial ownership below the 5% threshold, not indicating a significant change in investment thesis or company performance.

Positives

• Nantahala Capital Management, an investment adviser, along with its managing members, holds a significant beneficial ownership of 2,040,245 shares (4.09%) in Trisalus Life Sciences, Inc., indicating institutional interest.

Negatives

• The reporting persons certify that the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer, indicating a passive investment approach.

Risks

• No company-specific operational or financial risks are disclosed in this beneficial ownership report.

Future Outlook

This filing is a disclosure of beneficial ownership and does not contain any forward-looking statements or guidance regarding the issuer's future outlook.

Industry Context

This filing is a routine disclosure of institutional ownership and does not provide specific insights into broader industry trends or competitive landscape for Trisalus Life Sciences, Inc.

Stakeholder Impact

• Shareholders: Provides transparency regarding institutional ownership by Nantahala Capital Management and its managing members.

Key Dates

Keywords

Trisalus Life Sciences, Nantahala Capital Management, Wilmot B. Harkey, Daniel Mack, Schedule 13G, beneficial ownership, common stock, institutional ownership, investment adviser